Encompass Health (NYSE:EHC) Price Target Raised to $95.00 at Mizuho

Encompass Health (NYSE:EHC) had its target price raised by Mizuho from $93.00 to $95.00 in a research report sent to investors on Thursday, Benzinga reports. Mizuho currently has a buy rating on the stock.

EHC has been the subject of several other research reports. Truist Financial upped their price objective on shares of Encompass Health from $82.00 to $86.00 and gave the company a buy rating in a research note on Friday, February 9th. Stephens reaffirmed an overweight rating and set a $85.00 price objective on shares of Encompass Health in a research note on Tuesday, January 16th. Barclays increased their price target on shares of Encompass Health from $95.00 to $101.00 and gave the company an overweight rating in a research note on Thursday, March 28th. William Blair reissued an outperform rating on shares of Encompass Health in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada reissued an outperform rating and issued a $83.00 price target on shares of Encompass Health in a research note on Friday, February 9th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of Buy and an average price target of $85.44.

Encompass Health Stock Down 0.1 %

EHC opened at $82.74 on Thursday. Encompass Health has a fifty-two week low of $57.55 and a fifty-two week high of $85.84. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.28 and a current ratio of 1.28. The company has a fifty day moving average of $78.07 and a two-hundred day moving average of $70.76. The stock has a market capitalization of $8.29 billion, a price-to-earnings ratio of 22.36, a PEG ratio of 1.53 and a beta of 0.94.

Encompass Health (NYSE:EHC) last released its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.48%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the company earned $0.88 earnings per share. The company’s quarterly revenue was up 13.4% on a year-over-year basis. On average, research analysts expect that Encompass Health will post 3.96 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Monday, April 1st were issued a dividend of $0.15 per share. The ex-dividend date was Thursday, March 28th. This represents a $0.60 dividend on an annualized basis and a yield of 0.73%. Encompass Health’s dividend payout ratio (DPR) is presently 16.22%.

Institutional Investors Weigh In On Encompass Health

Hedge funds have recently added to or reduced their stakes in the business. New York State Teachers Retirement System raised its holdings in shares of Encompass Health by 6.8% in the 1st quarter. New York State Teachers Retirement System now owns 73,166 shares of the company’s stock valued at $6,042,000 after purchasing an additional 4,670 shares in the last quarter. Horrell Capital Management Inc. raised its holdings in shares of Encompass Health by 0.5% in the 1st quarter. Horrell Capital Management Inc. now owns 29,371 shares of the company’s stock valued at $2,425,000 after purchasing an additional 147 shares in the last quarter. Equitable Trust Co. raised its holdings in shares of Encompass Health by 69.4% in the 1st quarter. Equitable Trust Co. now owns 6,429 shares of the company’s stock valued at $531,000 after purchasing an additional 2,634 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Encompass Health by 75.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 720,173 shares of the company’s stock valued at $59,472,000 after purchasing an additional 310,285 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in Encompass Health by 15.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 55,111 shares of the company’s stock worth $4,551,000 after acquiring an additional 7,225 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.